Menu
iPMI Magazine Is Proudly Sponsored By:
For a healthier journey.

iPMI Magazine Has Moved

iPMI Magazine successfully rebranded to iPMI Global in 2023 and has moved to a new home on the internet. To visit the brand new international private medical insurance business intelligence platform, please go to www.ipmiglobal.com

Syntermed’s SyncTool™ Software to Be Used in International Heart Failure Clinical Trial

Syntermed, Inc., have announced that their SyncTool™ nuclear cardiology imaging software is being used in a large global clinical trial for the diagnosis of heart failure.

The VISION-CRT trial, sponsored by the International Atomic Energy Agency (IAEA), a branch of the United Nations, involves heart failure patients in nine countries (Italy, Algeria, South Africa, Pakistan, India, Colombia, Brazil, Mexico, and Vietnam). This study will include phase analysis for LV Dyssynchrony. SyncTool is a phase analysis software tool that analyzes the benefits of cardiac resynchronization therapy (CRT) in heart failure patients.

“SyncTool software is currently available for myocardial perfusion SPECT and PET, as well as, FDG-PET nuclear cardiology studies. Its inclusion in the global clinical trial underscores the flexibility of this technology for heart health around the world,” said Michael Lee, CEO, Syntermed, Inc.

“You cannot perform a 3-D or stress echo in all patients,” adds Ernest V. Garcia, PhD, Director of Nuclear Cardiology R&D at Emory University and a principal investigator in the VISION-CRT trial. “But all patients can undergo a nuclear cardiology gated SPECT study.”

The VISION-CRT clinical trial is designed to help improve the heart failure diagnosis in at-risk groups of people and to improve patient selection for cardiac resynchronization therapy. Given the morbidity and mortality from heart failure, as well as, the considerable resources that are used to diagnose and treat these patients, appropriate diagnosis and prognosis assessment are vital. Emory University nuclear cardiology researchers have been at the forefront of research evaluating SPECT MPI versus Speckle Tracking Echocardiology (STE) for the diagnosis of heart failure.

Ji Chen, PhD, Associate Professor of Radiology and Nuclear Cardiology R&D at Emory University says, “Of all heart failure patients, about two-thirds of the patients getting CRT will benefit from that treatment yet one-third will not. Phase analysis of left ventricular dyssynchrony can help with two critical issues: First, how to select the right patient for CRT; and second, where to put the left ventricular lead.” Studies show that the patients respond more favorably if the left ventricular lead is positioned in the right place.

back to top